Metabolic syndrome among a Ghanaian cohort living with HIV initiated on dolutegravir in a real-world setting: a prospective study
Authors:
Open Access
Abstract
Objectives The use of antiretroviral therapy has been linked to the development of some components of metabolic syndrome (MetS), specifically glucose intolerance, weight gain and defective lipid metabolism. This study determined the relationship between dolutegravir (DTG) and MetS in a cohort of persons living with HIV (PWH) initiating DTG-based regimen in Ghana. Design A 2-year observational prospective study was conducted from September 2020 to August 2022. Setting Five HIV high-burden facilities providing antiretroviral therapy services at the district and tertiary levels of care in Ghana. Participants Persons with HIV who were newly enrolled onto DTG. Primary and secondary outcome measures Waist circumference, body mass index, blood pressure, fasting blood glucose and lipids were the primary outcomes measured at baseline, 3, 6, 12 and at 18 months follow-up to determine the incidence of MetS. MetS was defined using the Joint Consensus definition that combines the International Diabetes Federation and the National Cholesterol Education Programme Adult Treatment Panel III (ATP III) definitions. The Kaplan-Meier estimator was used to estimate the risk of developing MetS. The Cox proportional hazard model was used in estimating HRs. Results Of 3664 PWH screened at baseline, 31.4% (1152/3664) had MetS. Of the remaining 2512 with no MetS at baseline, there were 960 incident cases of MetS over the 1.5 years follow-up. The estimated MetS incident rate is 384.2 (95% CI: 360.6 to 409.2) per 1000 person-years with a median time to development of MetS at 6 months (IQR; 3–12 months). Being female (adjsuted HR, aHR: 1.42, 95% CI: 1.19 to 1.70), age ≥50 years (aHR: 1.30, 95% CI: 1.12 to 1.51), having a comorbidity at baseline (aHR: 1.39, 95% CI: 1.12 to 1.51) and being overweight (aHR: 1.46, 95% CI: 1.25 to 1.71) and obese (aHR: 1.62, 95% CI: 1.36 to 1.93) were associated with higher risk of MetS development. Conclusions The incidence of MetS was high among our patients, with elevated fasting blood sugar and elevated blood pressure being the most common developed MetS defining components. HIV programmes should institute targeted interventions at addressing central obesity to reduce the risk of MetS.Keywords
Funding Information
- Global Fund to Fight AIDS, Tuberculosis and Malaria
- Ghana health service
This publication has 67 references indexed in Scilit:
- Metabolic syndrome among treatment‐naïve people living with and without HIV in Zambia and Zimbabwe: a cross‐sectional analysisJournal of the International AIDS Society, 2022
- Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failuresJournal of Global Antimicrobial Resistance, 2022
- Socioeconomic differences in metabolic syndrome development among males and females, and the mediating role of health literacy and self-management skillsPreventive Medicine, 2022
- The burden of metabolic syndrome in patients living with HIV/AIDS receiving care at referral hospitals of Northwest Ethiopia: A hospital-based cross-sectional study, 2019Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and CanadaJournal of the International AIDS Society, 2020
- Metabolic Syndrome Among People Living with HIV Receiving Medical Care in Southern United States: Prevalence and Risk FactorsAIDS and Behavior, 2019
- Anthropometric parameter that best predict metabolic syndrome in South west NigeriaDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019
- Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional studyInternational Journal of Infectious Diseases, 2018
- Metabolic syndrome in HIV-infected middle-aged women on antiretroviral therapy: prevalence and associated factorsThe Brazilian Journal of Infectious Diseases, 2017
- Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 WeeksClinical Drug Investigation, 2015